AMARIN CORP PLC\UK Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
AMARIN CORP PLC\UK (AMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.35% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2023-03-01
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.35%, a 219.85% increase from fiscal 2021.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.36%, a 21.84% decline from fiscal 2020.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.74%, a 41.02% decline from fiscal 2019.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.95%, a 1.67% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2022-12-31 | 4.35% 10-K · filed 2023-03-01 |
| 2021-12-31 | 1.36% 10-K · filed 2023-03-01 |
| 2020-12-31 | 1.74% 10-K · filed 2023-03-01 |
| 2019-12-31 | 2.95% 10-K · filed 2022-03-01 |
| 2018-12-31 | 3.00% 10-K · filed 2021-02-25 |
| 2017-12-31 | 2.01% 10-K · filed 2020-02-25 |
| 2016-12-31 | 1.70% 10-K · filed 2019-02-27 |
| 2015-12-31 | 1.68% 10-K · filed 2018-02-27 |
| 2014-12-31 | 1.68% 10-K · filed 2017-03-01 |
| 2013-12-31 | 2.07% 10-K · filed 2016-02-25 |
| 2012-12-31 | 1.39% 10-K · filed 2015-03-03 |
| 2011-12-31 | 2.56% 10-K · filed 2014-02-27 |
| 2010-12-31 | 3.10% 10-K · filed 2013-02-28 |
| 2009-12-31 | 3.00% 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |